Linagliptin

Aha kemịkalụ:

8-[(3R) -3-aminopperidin-1-yl] -7- (ma-2-yn-1-yl) -3- methyl-1-[(4-methylquinazolin-2-yl) methyl]-3 ,7-dihydro-1H-purine-2,6-dione

Koodu Ọchịchọ:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5=N4)C1 =O

Koodu InChi:

InChi=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33 (23 (21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

Igodo InChi:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Okwu:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Solubility:Soluble na DMSO

Nchekwa:0 - 4 Celsius C maka obere oge (ụbọchị ruo izu), ma ọ bụ -20 Celsius maka ogologo oge (ọnwa).

Nkọwa:

Linagliptin, makwaara dị ka BI-1356, bụ ihe mgbochi DPP-4 nke Boehringer Ingelheim mepụtara maka ọgwụgwọ ụdị ọrịa shuga II. Linagliptin (otu oge kwa ụbọchị) bụ ndị US FDA kwadoro na 2 Mee 2011 maka ọgwụgwọ ụdị ọrịa shuga II. Boehringer Ingelheim na Lilly na-ere ya.

Ebumnuche: DPP-4